On November 21st, 2016 the U.S. Food and Drug Administration approved SOLIQUA™ 100/33. SOLIQUA 100/33 is an injectable prescription medicine that contains 2 diabetes medicines, insulin glargine and lixisenatide, that may improve blood sugar (glucose) control in adults with type 2 diabetes. It is indicated for daily use with diet and exercise in people who are not controlled with long-acting (basal) insulin (less than 60 units daily) or lixisenatide. It will be available in a convenient single one-use pen.
Thank you to all of our clients who participated in this clinical trial. New drugs would not come to market without the significant effort put forth by all.
